Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Generation of a new bioluminescent model for visualisation of mammary tumour development in transgenic mice.

Zagozdzon AM, O'Leary P, Callanan JJ, Crown J, Gallagher WM, Zagozdzon R.

BMC Cancer. 2012 May 30;12:209. doi: 10.1186/1471-2407-12-209.

2.

Use of the ODD-luciferase transgene for the non-invasive imaging of spontaneous tumors in mice.

Goldman SJ, Chen E, Taylor R, Zhang S, Petrosky W, Reiss M, Jin S.

PLoS One. 2011 Mar 29;6(3):e18269. doi: 10.1371/journal.pone.0018269.

3.
4.

Dual-wavelength imaging of tumor progression by activatable and targeting near-infrared fluorescent probes in a bioluminescent breast cancer model.

Xie BW, Mol IM, Keereweer S, van Beek ER, Que I, Snoeks TJ, Chan A, Kaijzel EL, Löwik CW.

PLoS One. 2012;7(2):e31875. doi: 10.1371/journal.pone.0031875. Epub 2012 Feb 13.

5.

Heterogeneity of vascular and progenitor cell compartments in tumours from MMTV-PyVmT transgenic mice during mammary cancer progression.

Smith MJ, Berger RW, Minhas K, Moorehead RA, Coomber BL.

Int J Exp Pathol. 2011 Apr;92(2):106-16. doi: 10.1111/j.1365-2613.2010.00748.x. Epub 2010 Nov 8.

6.

Non-invasive detection of a small number of bioluminescent cancer cells in vivo.

Kim JB, Urban K, Cochran E, Lee S, Ang A, Rice B, Bata A, Campbell K, Coffee R, Gorodinsky A, Lu Z, Zhou H, Kishimoto TK, Lassota P.

PLoS One. 2010 Feb 23;5(2):e9364. doi: 10.1371/journal.pone.0009364.

7.

In vivo bioluminescent imaging of mammary tumors using IVIS spectrum.

Lim E, Modi KD, Kim J.

J Vis Exp. 2009 Apr 29;(26). pii: 1210. doi: 10.3791/1210.

8.

Noninvasive monitoring of changes in pancreatic beta-cell mass by bioluminescent imaging in MIP-luc transgenic mice.

Park SY, Bell GI.

Horm Metab Res. 2009 Jan;41(1):1-4. doi: 10.1055/s-0028-1087209. Epub 2008 Oct 23. Erratum in: Horm Metab Res. 2009 Jan;41(1):71.

9.
10.

Transgenic mice with mammary gland targeted expression of human cortactin do not develop (pre-malignant) breast tumors: studies in MMTV-cortactin and MMTV-cortactin/-cyclin D1 bitransgenic mice.

van Rossum AG, van Bragt MP, Schuuring-Scholtes E, van der Ploeg JC, van Krieken JH, Kluin PM, Schuuring E.

BMC Cancer. 2006 Mar 14;6:58.

11.

Use of mouse mammary tumour virus (MMTV)/neu transgenic mice to identify genes collaborating with the c-erbB-2 oncogene in mammary tumour development.

Jolicoeur P, Bouchard L, Guimond A, Ste-Marie M, Hanna Z, Dievart A.

Biochem Soc Symp. 1998;63:159-65. Review.

PMID:
9513720
12.
13.
14.

MMTV-Fgf8 transgenic mice develop mammary and salivary gland neoplasia and ovarian stromal hyperplasia.

Daphna-Iken D, Shankar DB, Lawshé A, Ornitz DM, Shackleford GM, MacArthur CA.

Oncogene. 1998 Nov 26;17(21):2711-7.

15.

Activated Akt1 accelerates MMTV-c-ErbB2 mammary tumourigenesis in mice without activation of ErbB3.

Young CD, Nolte EC, Lewis A, Serkova NJ, Anderson SM.

Breast Cancer Res. 2008;10(4):R70. doi: 10.1186/bcr2132. Epub 2008 Aug 13.

16.

The expression level of luciferase within tumour cells can alter tumour growth upon in vivo bioluminescence imaging.

Brutkiewicz S, Mendonca M, Stantz K, Comerford K, Bigsby R, Hutchins G, Goebl M, Harrington M.

Luminescence. 2007 May-Jun;22(3):221-8.

PMID:
17286245
17.
18.
19.

An immunocompetent murine model of metastatic mammary cancer accessible to bioluminescence imaging.

Shibata MA, Shibata E, Morimoto J, Eid NA, Tanaka Y, Watanabe M, Otsuki Y.

Anticancer Res. 2009 Nov;29(11):4389-95.

20.

Maspin expression inversely correlates with breast tumor progression in MMTV/TGF-alpha transgenic mouse model.

Reddy KB, McGowen R, Schuger L, Visscher D, Sheng S.

Oncogene. 2001 Oct 4;20(45):6538-43.

Supplemental Content

Support Center